Drug Utilization Review Board
Meeting Minutes, Open Session
April 19, 2023 10:00am – 2:00pm

Drug Utilization Review Board Due to COVID-19, this meeting was held virtually.	**Board Members:** Moneeshindra Mittal, MD, Chair James Backes, PharmD, Interim Chair Gregory Burger, PharmD, CPPS, FASHP, EMT Daryl Callahan, D.O, MSS Jennifer Clair, MD Kristen Powell, PharmD *(absent)* Michele Reisinger, DNP, APRN, FNP-BC *(absent)* Arthur Snow, MD Cori Durall, PharmD **KDHE-DHCF/Contractor Staff:** Annette Grant, RPh Victor Nguyen, PharmD Anh Rongish, PharmD, BCPS Sridevi Donepudi, MD Crystal Blackmon, Sr. Administrative Specialist **MCO Staff:** Mark DeMary, RPh, Aetna Better Health of Kansas Angie Yoo, PharmD, Sunflower State Health Plan Kelly Flannigan, PharmD, UnitedHealthcare Community Plan **Gainwell Technology Staff:** Karen Kluczykowski, RPh Kathy Kaesewurm, RN, BSN Harry Vu, PharmD Debra Illions-Clark, LPN Jordan Brazeal, PharmD	**Public attendees:** Jeff Knappen, Waleed Al-Homoud, Clemice Hurst, Jessica Chardoulias, Lee Stout, Karen Powell, Rhonda Clark, Lee Ward, Ash Dave, Beth Kingeter, John Bullard, Sara Hovland, Melissa Basil, Jamie Gideon, Serena Barden, Ricki Roberson, Gary Parenteau, Kurt Hendrickson, Kimbra Brooks, Jodi Jensen, Amanda Nowakowski, Heather Freml, Porscha Showers, C Donahue, Eric Hyde, Richie Crawford, K Witte, Rachna Kalia, Keith Gulley, Marc Parker, Robert Kilo, Paul Saskin, Garth Wright [Non-identified participants are not listed.]

TOPIC	DISCUSSION	DECISION
I. Call to Order A. Introductions B. Announcements	**Call to Order:** Dr. Mittal called the meeting to order at 10:14am and proceeded to take roll call for the board members. **Introductions:** None **Announcements:** Anh Rongish, PharmD, BCPS is a new pharmacist for the State. Harry Vu, PharmD from Gainwell Technologies is the new DUR support pharmacist	

TOPIC	DISCUSSION	DECISION
	for the State. Jordan Brazeal, PharmD will be assisting Gainwell Technologies with Fee-for-Service RDUR.	
II. Old Business A. Review and Approval of the January 18, 2022 Meeting Minutes	**Board Discussion:** Dr. Mittal asked if there were any amendments/changes to the minutes requested.	Dr. Snow moved to approve the minutes. Dr. Callahan second the motion. Motion to approve was carried unanimously.
III. New Business A. Executive Sign-off – Re-evaluation of Process (6 Month Follow Up)	**Background:** This agenda item pertains to the re-evaluation of the Executive Sign-off process, which was previously approved for six months at the October 2022 DUR meeting. **Public comment:** None **Board Discussion:** None	Dr. Callahan moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
B. Executive Sign-off Agenda Items – Revised Prior Authorization (PA) Criteria	**Background:** The 3 agenda items include: Enzyme Replacement Therapy, Minimum Requirements Prior Authorization (MRPA), and Oncology Agents. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Burger second the motion. Motion to approve was carried unanimously.
C. Revised Prior Authorization (PA) Criteria 1. Axial Spondyloarthritis Agents (formerly Ankylosing Spondylitis (AS) Agents)	**Background:** This revision includes revising the class' name, the re-evaluation of the treat-to-target strategy, and the addition of Amjevita™ to the list of agents requiring prior authorization. **Public comment:** Ash Dave (Amgen) spoke on behalf of Amjevita™ and to request the Board for access to the medication. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Callahan second the motion. Motion to approve was carried unanimously.
2. Diabetes Mellitus – Type 2 Agents	**Background:** This revision includes clarification of the HbA1c requirements, removal of metformin step-therapy, and re-evaluation of the renewal criteria. **Public comment:**	Dr. Backes moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
	Jessica Chardoulias (Novo Nordisk) recommended that the criteria be changed to remove the 90-day metformin trial requirement to align with current guidelines. **Board Discussion:** The Board discussed the renewed focused on cardiovascular and renal outcomes, regardless of A1c. The State will bring this topic back for discussion at the July DUR Meeting.	
3. Multiple Sclerosis (MS) Agents	**Background:** This revision includes the addition of Briumvi™ and Tascenso ODT® to the list of agents requiring prior authorization, proposal of step-therapy, and updates a blanket statement regarding other FDA-approved indications. **Public comment:** Jodi Jensen (Biogen) yielded her time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Backes second the motion. Motion to approve was carried unanimously.
4. Opioid Use Disorder (OUD) Agents	**Background:** This revision includes the removal of the XDEA number requirement in observance of recent changes in federal statute. Other minor formatting and standard language updates are also included. **Public comment:** None **Board Discussion:** None	Dr. Snow moved to approve. Dr. Burger second the motion. Motion to approve was carried unanimously.
5. Alzheimer's Disease Agents (formerly Aduhelm)	**Background:** Among other various revisions, this criteria expands the existing single agent PA to a class PA with the addition of Leqembi™ to the list of agents requiring prior authorization. **Public comment:** None **Board Discussion:** The Board discussed the disease scoring tools and the potential for provider burden if there are additional costs or training needed for use. Alternatives could be SLUMS and MOCA. The State will review these tools to ensure	Dr. Snow moved to approve. Dr. Clair second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
	there will not be extra financial or burden for providers and bring for discussion at the next DUR board meeting in July.	
6. Adult Rheumatoid Arthritis (RA) Agents	**Background:** This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization and updates a blanket statement regarding other FDA-approved indications. **Public comment:** Ash Dave (Amgen) yielded his time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Callahan moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
7. Crohn's Disease (CD) Agents	**Background:** This revision includes the addition of Amjevita™ and Skyrizi® On-Body Injector prefilled cartridges to the list of agents requiring prior authorization. **Public comment:** Ash Dave (Amgen) yielded his time back to the Board with the offer to answer any questions. Heather Freml (Abbvie) yielded her time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Backes second the motion. Motion to approve was carried unanimously.
8. Psoriatic Arthritis (PsA) Agents	**Background:** This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization, updates to indicated age for Stelara®, and updates a blanket statement regarding other FDA-approved indications. **Public comment:** Ash Dave (Amgen) yielded his time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Snow moved to approve. Dr. Clair second the motion. Motion to approve was carried unanimously.

TOPIC	DISCUSSION	DECISION
9. Ulcerative Colitis (UC) Agents	**Background:** This revision includes the addition of Amjevita™ to the list of agents requiring prior authorization, a minor clarification in the footnote of Table 1, and reorganization of the references. **Public comment:** Ash Dave (Amgen) yielded his time back to the Board with the offer to answer any questions. **Board Discussion:** None	Dr. Callahan moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
D. <u>Tentative Agenda Items (MHMAC and PDL Meeting Agenda Items)</u> 1. PDL Meeting (January 17, 2023) – New PDL Classes a. Sleep Agents – Scheduled – Orexin Receptor Antagonists: Belsomra®, Dayvigo®, and Quviviq™	**Background:** Addition of a new PDL class for scheduled sleep agent products. **Public comment:** Paul Saskin (Idorsia) spoke on behalf of Quviviq™, its efficacy and safety profile and asked that the Board consider adding this PDL drug class. **Board Discussion:** None	Dr. Callahan moved to approve. Dr. Snow second the motion. Motion to approve was carried unanimously.
E. <u>Miscellaneous Items</u> 1. Fee-for-Service Retrospective Drug Utilization Review Topic Selections	**Background:** Dr. Brazeal presented several FFS RDUR interventions topics for the DUR Board to choose from. The two interventions would be performed between May and June 2023. **Board Discussion:** The Board discussed choosing interventions that would have the largest impact on preventing death. “Underutilization of Biktarvy and Genvoya” and “Diabetes and CVD without claim for statin” were nominated.	Dr. Burger moved to approve. Dr. Callahan second the motion. Motion to approve was carried unanimously.
IV. Adjourn	The meeting adjourned at 12:03pm.	Dr. Snow motioned to adjourn. Dr. Backes seconded the motion. Motion to adjourn was carried unanimously.

The next DUR Board meeting is scheduled for July 19, 2023.

*Public comment is limited to five minutes per product; additional time will be allowed at the DUR Board’s discretion.
Informal comments will be accepted from members of the audience at various points in the agenda.
All approved PA criteria are posted to the KDHE website: https://www.kdhe.ks.gov/206/General-Clinical-Prior-Authorization